NIHR Medicines for Children Research Network (MCRN), Department of Women's and Children's Health, Institute of Translational Medicine, University of Liverpool, Alder Hey Children's NHS Foundation Trust, Liverpool L12 2AP, UK.
Expert Rev Clin Pharmacol. 2013 Sep;6(5):581-7. doi: 10.1586/17512433.2013.831531.
The need to evaluate medicines for children is widely acknowledged due to pervasive unlicensed medicine use in the pediatric setting. The EU Paediatric Regulation was developed to address these considerations, which subsequently led to the establishment of the National Institute of Health Research (NIHR) Medicines for Children Research Network (MCRN) in England. MCRN supports public and industry studies, and facilitates feasibility, site setup, recruitment and other services. The MCRN and other networks are members of the European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA). Enpr-EMA was established to foster and coordinate research, and develop collaborations across Europe. MCRN works with Enpr-EMA, industry and others to improve the conduct of research for the benefit of children's health.
由于儿科环境中普遍存在未注册药物的使用，因此广泛认为需要评估儿童用药。欧盟儿科法规就是为了解决这些问题而制定的，这随后导致了英国国家卫生研究院（NIHR）儿童药物研究网络（MCRN）的成立。MCRN 支持公共和行业研究，并促进可行性、站点设置、招募和其他服务。MCRN 与其他网络都是欧洲药品管理局（Enpr-EMA）儿科研究网络的成员。Enpr-EMA 的成立旨在促进和协调研究，并在欧洲范围内发展合作。MCRN 与 Enpr-EMA、行业和其他方面合作，以改善儿童健康研究的实施。
